Paroxysmal nocturnal hemoglobinuria (PNH) arises from somatic mutation of a bone marrow progenitor that disrupts glycosylinositol phospholipid (GPI) anchoring of cell surface proteins. We recently characterized the expression of GPIanchored decay accelerating factor (DAF) and CD59 during hematopoietic development in PNH marrow. We found that, although a subset of early hematopoietic precursors identified by the CD34+CD38-phenotype exhibits normal DAF and CD59 expression, DAF and CD59 are absent on the majority of CD34+CD38-cells. Pluripotent CD34TD38-hematopoietic stem cellr normally circulate in the peripheral blood and can be collected by apheresis, cryopreserved, and later used for reconstitution of hematopoiesis. In this study, we examined the phenotypes of CD34+ cells that are released into AROXYSMAL nocturnal hemoglobinuria (PNH) is a hematopoietic stem cell disorder that results in the generation of circulating blood elements that are abnormally sensitive to autologous complement. Though a rare disease (1 to 10 per 1,000,OOO population), analyses of its pathophysiology have provided remarkable insights into basic mechanisms of complement physiology and membrane biochemistry.',' The complement sensitivity of the affected cells is caused by the lack of two membrane regulators that normally protect blood cells from autologous complement attack: the decay accelerating factor (DAF), which inhibits the expression of autologous C3 convertases, and the membrane inhibitor of reactive lysis (CD59), which interferes with the assembly and insertion of autologous membrane attack complexes. Many of the symptoms that characterize the disorder are explained by the absence of these two proteins. However, other proteins are concomitantly missing from affected cells.
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The membrane protein deficiency in PNH arises from a defect in the linking of a subclass of surface proteins to biomembranes. Unlike most cell surface proteins that are anchored by membrane-spanning polypeptide sequences, proteins that are absent in PNH are attached via posttranslationally added glycoinositol phospholipid (GPI) moieties. The inability of affected cells to express these proteins is caused by a defect in the synthesis of N-acetyl-D-glucosamine-inositol phospholipid, the initial intermediate of GP1 anchor assembly. The genetic lesion underlying this biosynthetic defect resides in an X chromosome-linked gene termed PZG-A. 3 All PNH patients analyzed to date have shown mutations of this gene, though mutations in each case have been at different l~c i .~-~ Despite the advances that have been made in understanding the biochemical mechanisms underlying PNH, treatment of the disorder has remained largely supportive. In a small number of cases, allogeneic bone marrow transplantation (BMT) has been employed as used in other clonal stem cell disorders'," to reconstitute normal hematopoiesis. However, the use of this procedure has been reserved for patients in end-stage disease and frequently has been associated with complications including graft rejection, graft-versus-host disease, infection secondary to immunosuppression, and infection andor hemorrhage resulting from pancytopenia. In PNH, normal hematopoietic precursors coexist with affected stem cells in the marrow. Therefore, in principle, autologous BMT could be feasible if sufficient numbers of unaffected stem cells could be harvested, separated from affected stem cells, and returned to myeloablated patients. In recent years, peripheral blood stem cell harvests" have been used as a source of stem cells for autologous marrow transplantation. With this procedure, pluripotent stem cells can be collected from the circulation by cytapheresis, cryopreserved, and then reinfused into patients in a manner similar to that used for traditional BM harvests." Cytokine pretreatment can be used to promote progenitor release into the circulation before cytapheresis," and multiple procedures can be performed to increase the numbers of progenitors harvested. The present study was undertaken to determine whether peripheral stem cell harvest is a viable means of obtaining unaffected progenitor cells in patients with PNH. ) were present in the peripheral blood. Control subjects were healthy laboratory personnel or were patients undergoing autologous peripheral blood progenitor cell harvest for lymphoma or solid tumors who were in remission at the time of study.
MATERIALS AND METHODS

Proteins
Cyrapheresis. Peripheral blood mononuclear cell harvests were collected using a COBE Spectra blood cell separator (Lakewood, C0).l5 Control subjects in some cases received prior subcutaneous injections of recombinant granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to increase the stem cell yield. In some instances, mononuclear cells were cryopreserved in IO%.dimethyl sulfoxide (final concentration) using a controlled-rate liquid-nitrogen freezer and stored in liquid nitrogen. Thawed cells were washed three times with RPM1 containing 0.2 mglmL DNAse 1 (Sigma Chemical CO, St Louis, MO).
Cell preparation andjow cyrometry. Before staining, cells were washed three times in phosphate-buffered saline (PBS) containing 1 % BSNO. I % NaN3 and resuspended to I X 1 O' /mL. Resuspended cells (0. In contrast, the bottom right-hand plot containing data from the PNH patient shows two populations of CD34' cells: DAF' and DAF-.
concentrations of Streptavidin-PE. After washing two times, cells were resuspended to 1 mL in PBS containing 0.5% paraformaldehyde.
Flow cytometric analyses were performed on a FACStar Plus (Becton Dickinson) or a modified FACScan, which is equipped with an Argon ion laser tuned at 488 nm and a 633-nm HeNe laser. The HeNe permits the use of APC as a fluorochrome. Correction for the cross-over of fluorescence between two or more detectors was performed as de~cribed.".'~ Light scatter and two or three fluorescence signals were determined for each cell.
Data acquisition was performed with the Lysis I1 software (Becton Dickinson). For each experiment, two data files were collected. For the first data file, 15,000 to 30,000 events were collected without the use of gates to determine the frequency of CD34' cells. For the second data file, gates were used on both light-scatter parameters, and CD34' fluorescence and the entire sample originally containing 10' cells was collected. Data analysis was performed using the Lysis I1 or Paint-A-Gate Prosoftware (Becton Dickinson).
RESULTS
CD34+ cells circulate in the peripheral blood at low frequencies.'" To investigate whether these circulating CD34+ cells normally express DAF and CD59 homogeneously and whether they derive from affected or unaffected hematopoiesis in PNH, apheresis samples from controls and PNH patients were stained with CD34-FITC and DAF-PE. Flow cytometric analyses of harvests from two control subjects and one PNH patient are shown in Fig 1. Gates were set on forward scatterkide scatter to increase the proportion of CD34' stem cells analyzed. In all three cases, cells staining for CD34 were seen at the expected frequency, ie, 0.01% to 0.1 % of the mononuclear cells.'* In accordance with previous characterizations of CD34' cells in m a r r~w ,~~. '~ in the two control subjects, all peripheral blood CD34' cells were uni- The majority of CD34' progenitor cells are committed to one of the hematopoietic cell lineages." Pluripotent nonlineage committed progenitor cells are present in a subset of CD34 cells that lack CD38 antigen.Ix Expression of DAF and CD59 by CD34TD38' and CD34TD38-cells in the apheresis sample from a control subject and from the above studied PNH patient are shown in Fig 2, A and E, and B and F, respectively. In the figure, only CD34' cells are shown and the expression of CD38 is plotted versus the expression of DAF or CDS9. Four phenotypes are distinguished: (1) CD34'CD38'DAF'CDS9' (upper gray dots), (2) CD34TD38-DAFTD59' (lower gray dots), (3) CD34'CD38'DAF-CDS9-(upper black dots), and (4) CD34'CD38-DAF-CDS9-(lower black dots). As seen in the figure, in the case of the control subject, both committed CD34TD38' and uncommitted CD34'CDW cells expressed DAF and CD59 homogeneously. In contrast, in the PNH patient, cells lacking DAF and CD59 were observed in the most primitive CD34'CD38-cell population. Unexpectedly, a higher proportion of unaffected DAF' CDS9'CD34'CD38-progenitor cells was seen as compared with affected DAF-CDWCD34TD38-cells (see Table l ).
Flow cytometric analyses of peripheral blood harvests of two other PNH patients are shown in Fig 2, C and G, and D and H, respectively. As observed with the first patient, discrete populations of peripheral blood DAF-CDS9-CD34' and DAF'CDS9'CD34' stem cells were distinguishable in each case. Likewise, as noted in the first patient, the numbers of unaffected CD59'CD34'CD38-cells (lower grey dots) were greater than the numbers of affected peripheral blood CD59 TD34TD38-cells (lower black dots) present in each patient. (Because of greater fluorescence intensity, CD59 is a more accurate marker than DAF for the assessment of the %CD34, % of CD34' cells in leukopheresis; CD38'. % of CD38' cells within the CD34' cell population; DAF', %within indicated fraction which expresses CD55; CD38-, % of CD38-cells within the CD34' cell population; CD59'. %within indicated fraction which expresses CD59.
presence of GPI-anchored proteins.) In Table 1 the percent-CD59 (Fig 4) showed that in both cases, the great majority ages of peripheral blood CD34' cells and the proportions of of neutrophils that have short halftimes in the circulation CD34TD38' and CD34'CD38-cells that expressed DAF and, thus, reflect marrow production were affected. In Table  and However, for such transplantation to be feasible, practical methods must be devised to harvest these cells and return them to patients. The present study indicates that stem cells recovered from apheresis samples could be used as a source of progenitor cells for hematopoietic reconstitution in PNH. Indeed, it may be a desirable source because, compared with BM harvest, peripheral stem cell harvest is less traumatic and can be performed repeatedly without anesthesia." Although a paired BM sample was available for analysis in only one patient, it may be presumed that the proportion of affected stem cells in all three patients is high because greater than 90% of mature circulating neutrophils that have been considered an accurate marker of BM production were affected in the other two cases. Although cytapheresis samples could be obtained on only three patients, unexpectedly, we found that the CD34TD38-cells present in the circulation of all three patients were predominantly CD59+ (see Fig 3 and Table 2). Thus, our findings indicate that unaffected progenitors are efficiently released from the marrow in PNH patients and circulate normally as in healthy individuals. It is noteworthy that in one patient (patient A), analyses of circulating progenitors showed that greater than 70% (in two different studies) were unaffected, as compared with only 2% to 9% DAF'CD59' neutrophils.
The mechanism of the apparently greater representation of unaffected CD34TD38-cells in the circulation of patients is unknown. One possibility is that one or more GPIanchored proteins could play a role in adherencehoming reactions that are involved in stem cell transfer from the marrow to the circulation. A second possibility is that affected DAF-CD59-CD34' cells are somehow protected from complement in the marrow, but upon transfer to the blood, either are destroyed andor eliminated, or are induced to differentiate as a result of autologous complement attack.
A number of questions remain before autologous hematopoietic reconstitution can be exploited clinically. First, purification methods, using anti-CD59 or anti-DAF affinity chromatography or possibly complement lysis, must be developed to selectively purify unaffected DAF'CD59TD34' cells from stem cell harvests. Second, further questions must be answered regarding basic pathophysiologic mechanisms underlying PNH. Some evidence indicates that unaffected stem cells in PNH marrow grow at a slower rate than stem cells of normal individuals, an implication that the hematopoietic microenvironment in PNH patients may provide a proliferative disadvantage to unaffected progeniton2 Support for this hypothesis comes from the fact that up to 25% of PNH cases evolve either from or into aplastic anemia.'.2 Other evidence suggests that the affected PNH clone may have a relative proliferative advantage such that it is able to expand despite the presence of much larger numbers of unaffected stem cells.* In support of such an advantage, the growth of PNH marrow cells in the absence of stimulating growth factors has been reported."
Notwithstanding the above considerations, further studies need to be performed to make autologous transplantation 
